Evidence library · 32 records
Findings attach to claims, not whole peptides. Search by compound or outcome, then read the evidence basis, verdict, confidence and date together.
The peptide evidence library contains 32 claim-level records. Each record separates what research exists from what that research can support, so a preclinical evidence basis does not become a human benefit claim and a supported narrow outcome does not become a whole-compound endorsement.
The original 30 records were checked and reviewed on 10 August 2026. Two records were added, and the BPC-157 recovery/pain record received a literature update, following scientific and clinical sign-off confirmed on 6 September 2026. Each record retains its source dates.
Claim register
Showing 32 of 32 records
Claim assessed: This laboratory paper establishes the safety or equivalence of a separate GLP-1 vial.
Claim assessed: This medical-record preprint verifies a retatrutide product or establishes its causal effects.
BPC-157 heals injured tendons and ligaments in people
BPC-157 speeds injury recovery and reduces pain in people
BPC-157 promotes gut or mucosal repair in people
TB-500 improves soft-tissue or wound healing in people
Defined long-acting CJC-1295 raises growth hormone and IGF-1 in healthy adults
CJC-1295 builds muscle or reduces body fat
Ipamorelin triggers short-term growth-hormone release in people
Ipamorelin improves recovery, muscle gain or body composition
GHRP-2, GHRP-6 and hexarelin acutely release growth hormone in people
Melanotan II increases visible skin pigmentation
Melanotan II can initiate erections in men with erectile dysfunction
Authorised semaglutide medicine produces weight loss in eligible adults
Authorised tirzepatide medicine produces weight loss in eligible adults
Retatrutide produces weight loss in adults with obesity or overweight
AOD-9604 produces clinically meaningful weight loss in adults with obesity
Injected MOTS-c improves metabolic health or physical performance in people
Forzinity (elamipretide) improves muscle strength in people with Barth syndrome who weigh at least 30 kg
Epitalon extends lifespan in people
Epitalon lengthens telomeres or activates telomerase in people
Semax improves cognitive or functional recovery after ischaemic stroke
Selank reduces anxiety symptoms in people with anxiety-spectrum conditions
DSIP improves sleep in people with chronic insomnia
KPV reduces gut inflammation or improves gut disease in people
Thymosin alpha-1 broadly boosts immunity in otherwise unspecified people
Topical LL-37 improves healing of venous leg ulcers
ARA-290 reduces neuropathic symptoms in sarcoidosis-associated small-fibre neuropathy
MGF or PEG-MGF increases muscle growth or recovery in people
Kisspeptin-54 triggers oocyte maturation in women at high risk of ovarian hyperstimulation syndrome during IVF
Authorised gonadorelin evokes LH and FSH responses for specialist diagnostic pituitary testing
US-authorised bremelanotide improves desire and related distress in premenopausal women with acquired, generalised HSDD
No records match those filters. Reset the filters or try a broader claim.
Read both fields
Evidence basis describes whether the claim has relevant human, limited human, preclinical, absent or conflicting evidence. Verdict states supported, mixed, unsupported or insufficient for the exact claim. Neither label rates the safety or value of a whole compound.
Use the scope
Start with the claim wording. Check whether the population, formulation and outcome match your question. Then read the evidence basis, verdict, confidence, limits and update trigger together.
No paper or authorisation can establish what is inside a different vial. Use the testing and COA guides for identity, quantity and microbiological questions.
If symptoms may be urgent, use the warning-sign route rather than an evidence record.
Editorial experience
For topical-map item C-003, Peptide evidence library was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 0 unique external sources and 36 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.